Cosmo Pharmaceuticals NV (COPN) EUR0.26

Sell:82.30 CHFBuy:86.90 CHFPrice increased0.50 CHF (0.58%)

Prices delayed by at least 15 minutes
Sell:82.30 CHF
Buy:86.90 CHF
Change:Price increased0.50 CHF (0.58%)
Prices delayed by at least 15 minutes
Sell:82.30 CHF
Buy:86.90 CHF
Change:Price increased0.50 CHF (0.58%)
Prices delayed by at least 15 minutes

Company Information

About this company

Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases, dermatology, and healthtech. Its development pipeline includes Distal Ulcerative Colitis, Bile Acid Diarrhea, Solid Tumors, and AI Augmented Endoscopy. The Company's developed products include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, which is used for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo, which is used for the treatment of travelers’ diarrhea (TD); Methylene Blue MMX, which is a diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy, and Winlevi, which is used for the treatment of acne. It also develops medical devices to assist with clinical decision-making.

Key people

Alessandro Della Cha
Non-Executive Chairman of the Board
Nhan Ngo Dinh
President - Cosmo Intelligent Medical Devices, Member of the Management Board
Dominika Spilarova
Chief Strategy Officer, Member of the Management Board
Mauro Severino Ajani
Non-Executive Director
John O'Dea
Non-Executive Director
Silvana Perretta
Non-Executive Director
Maria Grazia Roncarolo
Non-Executive Director
Giovanni Di Napoli
Chief Executive Officer, Executive Director, Member of the Management Board
Svetlana Sigalova
Chief Financial Officer, Member of the Management Board
Silvia Miliani
Chief Human Resources Officer
Niall Donnelly
Executive Vice President - Corporate Governance and Chief Sustainability Officer, Executive Director, Member of the Management Board
Luigi Longo
Chief Scientific Officer, Member of the Management Board
Federico Sommariva
Chief Legal Counsel
Andrea Cherubini
Chief Artificial Intelligence Officer, Member of the Management Board
Egle Gedrimaite
Member of the Management Board, Head - Global Business Development
Click to see more

Key facts

  • Shares in issue
    17.54m
  • EPIC
    COPN
  • ISIN
    NL0011832936
  • Location
    Ireland
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    CHF 1.53bn
  • Employees
    325
  • Exchange
    SIX Swiss Exchange
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.